The pathophysiological role of renal dopaminergic activity in patients with essential hypertension. 1987

O Iimura, and I Yamaji, and K Kikuchi, and S Shibata, and M Nishimura, and A Nozawa, and K Aoki, and T Hasegawa, and H Kobayakawa, and H Komura
Second Department of Internal Medicine, Sapporo Medical College, Japan.

To evaluate the role of the renal dopaminergic system on renal water-sodium metabolism patients with essential hypertension (EHT), urinary excretion of dopamine, urinary excretion of sodium (UNaV) and fractional excretion of sodium (FENa) were all investigated before and after the administration of dopamine (3 micrograms/kg/min, intravenous infusion for 60 minutes), dopamine antagonist, metoclopramide (8 mg/m2 BSA, intravenous injection) or mild sodium loading in both normotensive subjects and benign EHT. In the basal values, no significant difference in urinary excretion of free (u-fDA), conjugated (u-cDA) or total dopamine (u-tDA) was found between normotensives and hypertensives. However, low renin EHT showed a pronounced reduction in u-fDA compared with normotensis subject and (NT) normal renin EHT. In this study, a significant reduction of u-cDA and of u-tDA was also found in those patients with low renin essential hypertension. In the normotensive and essential hypertensive groups UNaV or FENa showed a positive correlation with u-fDA (measured simultaneously), but not with u-tDA or u-cDA. The regression line between u-fDA and UNaV or FENa in EHT was shifted towards a lower u-fDA level than in NT. UNaV and FENa were increased by dopamine infusion and were decreased by metoclopramide injection in both NT and EHT. Changes of UNaV and FENa following dopamine or metoclopramide, showed a negative correlation with u-fDA measured immediately before the administration of these drugs. The enhanced natriuretic response to infused dopamine and the attenuated antinatriuretic response to injected metoclopramide were significant in low renin EHT, when compared with NT or normal renin EHT patients.(ABSTRACT TRUNCATED AT 250 WORDS)

UI MeSH Term Description Entries
D006973 Hypertension Persistently high systemic arterial BLOOD PRESSURE. Based on multiple readings (BLOOD PRESSURE DETERMINATION), hypertension is currently defined as when SYSTOLIC PRESSURE is consistently greater than 140 mm Hg or when DIASTOLIC PRESSURE is consistently 90 mm Hg or more. Blood Pressure, High,Blood Pressures, High,High Blood Pressure,High Blood Pressures
D007262 Infusions, Intravenous The long-term (minutes to hours) administration of a fluid into the vein through venipuncture, either by letting the fluid flow by gravity or by pumping it. Drip Infusions,Intravenous Drip,Intravenous Infusions,Drip Infusion,Drip, Intravenous,Infusion, Drip,Infusion, Intravenous,Infusions, Drip,Intravenous Infusion
D007275 Injections, Intravenous Injections made into a vein for therapeutic or experimental purposes. Intravenous Injections,Injection, Intravenous,Intravenous Injection
D008297 Male Males
D008787 Metoclopramide A dopamine D2 antagonist that is used as an antiemetic. 4-Amino-5-chloro-N-(2-(diethylamino)ethyl)-2-methoxybenzamide,Cerucal,Maxolon,Metaclopramide,Metoclopramide Dihydrochloride,Metoclopramide Hydrochloride,Metoclopramide Monohydrochloride,Metoclopramide Monohydrochloride, Monohydrate,Primperan,Reglan,Rimetin,Dihydrochloride, Metoclopramide,Hydrochloride, Metoclopramide,Monohydrochloride, Metoclopramide
D008875 Middle Aged An adult aged 45 - 64 years. Middle Age
D009318 Natriuresis Sodium excretion by URINATION. Natriureses
D012083 Renin A highly specific (Leu-Leu) endopeptidase that generates ANGIOTENSIN I from its precursor ANGIOTENSINOGEN, leading to a cascade of reactions which elevate BLOOD PRESSURE and increase sodium retention by the kidney in the RENIN-ANGIOTENSIN SYSTEM. The enzyme was formerly listed as EC 3.4.99.19. Angiotensin-Forming Enzyme,Angiotensinogenase,Big Renin,Cryorenin,Inactive Renin,Pre-Prorenin,Preprorenin,Prorenin,Angiotensin Forming Enzyme,Pre Prorenin,Renin, Big,Renin, Inactive
D004298 Dopamine One of the catecholamine NEUROTRANSMITTERS in the brain. It is derived from TYROSINE and is the precursor to NOREPINEPHRINE and EPINEPHRINE. Dopamine is a major transmitter in the extrapyramidal system of the brain, and important in regulating movement. A family of receptors (RECEPTORS, DOPAMINE) mediate its action. Hydroxytyramine,3,4-Dihydroxyphenethylamine,4-(2-Aminoethyl)-1,2-benzenediol,Dopamine Hydrochloride,Intropin,3,4 Dihydroxyphenethylamine,Hydrochloride, Dopamine
D005260 Female Females

Related Publications

O Iimura, and I Yamaji, and K Kikuchi, and S Shibata, and M Nishimura, and A Nozawa, and K Aoki, and T Hasegawa, and H Kobayakawa, and H Komura
November 1996, Japanese heart journal,
O Iimura, and I Yamaji, and K Kikuchi, and S Shibata, and M Nishimura, and A Nozawa, and K Aoki, and T Hasegawa, and H Kobayakawa, and H Komura
January 1986, Journal of cardiovascular pharmacology,
O Iimura, and I Yamaji, and K Kikuchi, and S Shibata, and M Nishimura, and A Nozawa, and K Aoki, and T Hasegawa, and H Kobayakawa, and H Komura
November 1993, American journal of hypertension,
O Iimura, and I Yamaji, and K Kikuchi, and S Shibata, and M Nishimura, and A Nozawa, and K Aoki, and T Hasegawa, and H Kobayakawa, and H Komura
November 1991, Nihon Naibunpi Gakkai zasshi,
O Iimura, and I Yamaji, and K Kikuchi, and S Shibata, and M Nishimura, and A Nozawa, and K Aoki, and T Hasegawa, and H Kobayakawa, and H Komura
July 1988, Nihon Naibunpi Gakkai zasshi,
O Iimura, and I Yamaji, and K Kikuchi, and S Shibata, and M Nishimura, and A Nozawa, and K Aoki, and T Hasegawa, and H Kobayakawa, and H Komura
September 1991, American journal of hypertension,
O Iimura, and I Yamaji, and K Kikuchi, and S Shibata, and M Nishimura, and A Nozawa, and K Aoki, and T Hasegawa, and H Kobayakawa, and H Komura
January 1987, Agents and actions. Supplements,
O Iimura, and I Yamaji, and K Kikuchi, and S Shibata, and M Nishimura, and A Nozawa, and K Aoki, and T Hasegawa, and H Kobayakawa, and H Komura
June 1995, Hypertension research : official journal of the Japanese Society of Hypertension,
O Iimura, and I Yamaji, and K Kikuchi, and S Shibata, and M Nishimura, and A Nozawa, and K Aoki, and T Hasegawa, and H Kobayakawa, and H Komura
February 1983, Scandinavian journal of clinical and laboratory investigation,
O Iimura, and I Yamaji, and K Kikuchi, and S Shibata, and M Nishimura, and A Nozawa, and K Aoki, and T Hasegawa, and H Kobayakawa, and H Komura
April 1987, Journal of hypertension,
Copied contents to your clipboard!